Specifically Targeting Interleukin-13 With Tralokinumab Improved Sleep in Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials in Patients With Atopic Dermatitis. J of Skin 2021, 5 (1), s9. https://doi.org/10.25251/skin.5.supp.9.